What's the cheapest weight loss medication in 2026?

I looked at the pricing for all 7 FDA-approved weight loss drugs available in 2026. The spread is staggering. The cheapest option costs about the same as a streaming subscription. The most expensive runs more than many people's car payment.

Two years ago, the conversation about weight loss medication cost was more complicated than the list prices suggested. GLP-1 injections carried list prices of $1,000 or more per month, and without insurance that covered them, that rate priced many people out. Manufacturer self-pay prices existed even then — Eli Lilly began selling Zepbound vials at a self-pay price well below the list price in August 2024 — but not every GLP-1 drug had one.

Then GLP-1 pills arrived: Oral Wegovy (the semaglutide pill, approved December 2025) and Foundayo (orforglipron, approved April 2026). Both launched with self-pay prices starting at $149/month, well below the injections' list prices. The older drugs that were always affordable got even cheaper as generics expanded. The result is a landscape where most people can find something effective at a price they can actually sustain.

Here's every option, organised from cheapest to most expensive. Each one comes with the clinical trial data behind it, so you can weigh cost against effectiveness.

The budget tier: under $100 a month

If cost is the primary constraint, two FDA-approved options have been around for over a decade. Both are now available as generics or over the counter. Neither is as powerful as the newer GLP-1 drugs. But both have solid clinical evidence behind them, and they cost a fraction of the price.

Qsymia (phentermine/topiramate) runs $30–$80 per month depending on the pharmacy. It's a combination of a stimulant appetite suppressant and an anti-seizure drug that also reduces appetite. In the CONQUER trial, people on the full dose lost an average of 9.8% of their body weight over 56 weeks. That is roughly 22 lbs for someone starting at 220 lbs. The main side effects are tingling in the hands and feet (20% of people in trials) and dry mouth (21%). Some people report a kind of mental fog from the topiramate component. It's a controlled substance, so you'll need a prescription and regular follow-ups.

Alli (orlistat 60mg) is $40–$60 per month and available over the counter without a prescription. It works completely differently from every other drug on this list. Instead of suppressing appetite in the brain, it blocks about 30% of the fat you eat from being absorbed in the gut. The weight loss is more modest, around 5–6% of body weight in trials. The stomach side effects are well known: oily stools, urgency, and occasional accidents, especially if you eat high-fat meals. Many people find the side effects actually help them stick to a lower-fat diet. The 4-year XENDOS trial showed it reduced progression to type 2 diabetes by 37%. That is a meaningful health benefit beyond weight loss alone.

There is an older, cheaper corner of the prescription market that this list leaves out. Generic phentermine is a stimulant appetite suppressant. It is licensed for short-term use, rather than the open-ended treatment the newer drugs are approved for, and phentermine runs $10–$51/mo. Three others from the same era — diethylpropion, phendimetrazine and benzphetamine — are still approved but rarely prescribed. Each of those pages carries its own trial data and label wording, which is where the short-term limitation is spelled out.

The GLP-1 pill revolution: from $149 a month

This is where the landscape shifted. Until late 2025, GLP-1 drugs for weight loss were only available as injections — list prices ran to $1,000 or more per month, though manufacturer self-pay programmes (where they existed) brought the actual cost down for many people. That class includes Ozempic, Wegovy and Zepbound. Now there are two pill versions, each cheaper than the injections at every price point.

Oral Wegovy (semaglutide 25mg pill), approved in December 2025, produced 13.6% average weight loss in the OASIS 4 trial over 64 weeks. Among people who took it consistently, that figure climbed to 16.6%. It's priced by dose through Novo Nordisk's patient programme. Self-pay is $149 per month at the 1.5mg starting dose, rising to $299 per month at the 9mg and 25mg maintenance doses. With commercial insurance it can be as little as $25 per month, capped at $100/month in savings. The catch is the dosing ritual. You take it first thing in the morning on an empty stomach with no more than 4 ounces of water. Then you wait at least 30 minutes before eating or drinking anything else. For some people that's no big deal. For others, especially those with unpredictable morning routines, it's a genuine hassle.

Foundayo (orforglipron), approved in April 2026 by Eli Lilly, is the first GLP-1 pill with no food or water restrictions at all. Take it whenever you want, with or without food. In the ATTAIN-1 trial, it produced 12.4% average weight loss at the highest dose over 72 weeks. Pricing starts at $149 per month for the lowest dose and goes up to $349 per month for the highest dose through LillyDirect. With commercial insurance savings cards, it can drop to about $25 per month. Medicare Part D coverage is expected from July 2026 at around $50 per month.

The two pills differ mostly on convenience and dosing schedule rather than price. Oral Wegovy produced 13.6% average weight loss in its own trial (OASIS 4); Foundayo produced 12.4% in its own trial (ATTAIN-1) — separate trials, not a head-to-head comparison. Oral Wegovy requires a 30-minute fast before eating; Foundayo has no food or water timing restrictions at all. Same price tier, same drug class, different trade-offs. For most people, the one their insurance covers better will be the deciding factor.

The middle ground: $100–$400 a month

Contrave (naltrexone/bupropion) sits in this range at $100–$400 per month, depending on whether you get brand or generic. It's a twice-daily pill that combines an opioid blocker with an antidepressant. The weight loss is more modest, 6.1% in the COR-I trial. But it works on a completely different pathway than GLP-1 drugs. It targets the brain's reward and craving circuits. That makes it potentially more useful for people whose weight is driven by emotional eating or food cravings rather than pure appetite. The bupropion component also functions as an antidepressant, which can be a benefit or a complication depending on your situation. One important point: Contrave cannot be combined with opioid medications, because the naltrexone will block them.

The injection tier: Zepbound from $299

The injectable GLP-1 drugs have shown substantial weight loss in their trials, but they're also the most expensive. Whether the extra weight loss justifies the extra cost depends entirely on your financial situation and insurance coverage.

In the SURMOUNT-1 trial, Zepbound (tirzepatide) produced up to 20.9% average weight loss. It's a once-weekly injection that activates two appetite-regulating pathways (GIP and GLP-1) instead of just one. List price without the savings programme is about $1,086 per month. Eli Lilly's LillyDirect self-pay vials start at $299 per month for the 2.5 mg dose, and rise to $449 per month at 7.5 mg and above. For a 220 lb person, 20.9% weight loss translates to about 46 lbs.

Wegovy injection (semaglutide 2.4mg) is self-pay $349–$399/mo a month through Novo Nordisk's NovoCare Pharmacy. List price without that programme is about $1,349/month. It produced 14.9% average weight loss in the STEP 1 trial. It is also the only weight loss drug proven to reduce heart attacks and strokes: the SELECT trial showed a 20% reduction in major heart events. That trial specifically studied people with cardiovascular disease and overweight or obesity, not the general weight-loss population. The same drug is also available as a pill from $149 a month, if cost outweighs the slight difference in weight loss.

Saxenda (liraglutide) is an older daily injection at $1,000–$1,349/mo for the brand version. That is now the highest self-pay price of the seven approved drugs, because Saxenda has no manufacturer savings programme the way Zepbound and Wegovy do. A generic version is available at a typical saving of $135–$200 off that range. It produces less weight loss than the newer GLP-1 drugs, 6–8% in trials. It is now primarily used as a stepping stone: some insurers require you to try liraglutide before approving the more expensive options.

Insurance changes everything — but it's complicated

The self-pay prices above tell one story. Insurance tells a very different one. With the right coverage, a Wegovy injection priced at $1,349/month list price (or $349–$399/mo self-pay) can drop to $25/month. A $30/month generic might stay about the same. The problem is that coverage varies enormously: by insurer, by plan, by state, and by which drug you're asking about.

Most commercial insurance plans now cover at least one GLP-1 drug for weight loss. But almost all require prior authorisation. Your doctor has to submit paperwork proving you meet certain criteria, typically a BMI of 30 or above, or 27 with a weight-related health condition. Many plans also have step therapy requirements. That means trying a cheaper drug first and showing it didn't work, before they'll approve the more expensive one.

Medicare Part D has been a major gap. It historically didn't cover anti-obesity medications at all. That's changing in 2026. Coverage for Foundayo (orforglipron) is expected from July 2026 at approximately $50 per month. This is a significant shift for the millions of Medicare beneficiaries with obesity.

Both major GLP-1 manufacturers run savings programmes. Novo Nordisk's NovoCare savings card can bring Wegovy (injection or pill) down to about $25/month for commercially insured patients. Eli Lilly's LillyDirect programme offers Zepbound and Foundayo at reduced self-pay prices shipped direct to your door. These programmes are not available for Medicare, Medicaid, or other government-funded insurance.

Cost vs effectiveness: what the trade-off actually looks like

Semaglutide's injectable form (Wegovy) produced 14.9% average weight loss in its own trial (STEP 1); self-pay is $349–$399/mo a month. The cheapest GLP-1 pill, oral Wegovy, produced 13.6% average weight loss in its own trial (OASIS 4); self-pay is $149–$299/mo by dose. These figures come from separate trials, not a head-to-head comparison, so they should be read as separate results rather than a measured difference.

On the other hand, the lowest-priced of the seven drugs covered here is generic Qsymia, from $30/month. In its trial (CONQUER), people lost 9.8% of their body weight on average — a result from a different trial than the GLP-1 pills, so not a measured difference between them. The trade-off is different side effects: tingling, dry mouth and possible brain fog, against the stomach effects of GLP-1 drugs. It also works by a different mechanism, one that doesn't come with the heart benefits seen in the GLP-1 trials.

In its own trial (SURMOUNT-1), Zepbound (tirzepatide) showed up to 20.9% average weight loss. It costs $299–$449/month through LillyDirect, depending on the dose. The GLP-1 pills' figures come from different trials, so the gap between them is not a measured difference between the drugs. Whether a higher price is worth it is a personal financial question, not a medical one.